Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance

• Main Authors: Zhang, Chuanfen, Wang, Chunmei, Yang, Zhenyu, Bai, Yuquan, Shukuya, Takehito, Poh, Mau Ern, Ekman, Simon, Li, Jian, Xu, Yuyang, Deng, Senyi
• Format: Article
• Published: Ame Publ Co 2022
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/41461/

Tyrosine kinase inhibitor (TKI) treatment has significantly improved the prognosis of oncogenic-driven lung adenocarcinoma (LUAD). However, drug resistance limits the long-term benefits of patients. Therefore, there is a pressing need to explore the mechanism of TKI resistance and identify new thera...